Crown Bioscience

AUGUST 2, 2021

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52

Disease Drug Development Immune Response Drugs 52

DrugBank

MAY 15, 2024

The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.

Small Molecule 82

Small Molecule Molecular Biology Drugs Disease 82

Drug Target Review

OCTOBER 26, 2023

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively. Nature 578 , 229-236 (2020).

Engineering 105

Engineering Virus Therapies Immune Response 105

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

These include drugs that you may have heard about on the news: remdesivir (an antiviral), dexamethasone (a steroid), and monoclonal antibodies from the companies Eli Lilly and Regeneron. They are called immune modulators because they help to minimize the effects of an overactive immune response in some COVID-19 patients.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52